Dr Reddys Laboratories Ltd dividend

The Dividend per Share of Dr Reddys Laboratories Ltd is ₹ 40 as of 2024 .a1#The Dividend Payout of Dr Reddys Laboratories Ltd changed from 25.99 % on March 2019 to 15.37 % on March 2024 . This represents a CAGR of -8.38% over 6 years. a1#The Latest Trading Price of Dr Reddys Laboratories Ltd is ₹ 6892 as of 26 Jul 15:30 .a1#The Market Cap of Dr Reddys Laboratories Ltd changed from ₹ 46069 crore on March 2019 to ₹ 102679 crore on March 2024 . This represents a CAGR of 14.29% over 6 years. a1#The Revenue of Dr Reddys Laboratories Ltd changed from ₹ 6096 crore to ₹ 7314 crore over 8 quarters. This represents a CAGR of 9.54% a1#The EBITDA of Dr Reddys Laboratories Ltd changed from ₹ 1804 crore to ₹ 2032 crore over 8 quarters. This represents a CAGR of 6.12% a1#The Net Pr of Dr Reddys Laboratories Ltd changed from ₹ 1189 crore to ₹ 1309 crore over 8 quarters. This represents a CAGR of 4.96% a1#

Dr Reddy's Laboratories Ltd (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. In the year 1993, the company established Dr. Reddy's Research Foundation and initiated drug discovery programme. In the year 2003, they launched Ibuprofen, first generic product to be marketed under the 'Dr. Reddy's' label in the US. During the year 2010-11, the company acquired GlaxoSmithKline's (GSK) oral penicillin manufacturing facility located in Tennessee, USA. During the year, the company launched Cresp in India, the first biosimilar darbepoetin alfa in the world. This action follows the earlier inspections of these sites by the agency in November 2014, January 2015 and February 2015 respectively. On 8 February 2017, Dr. Reddy's Laboratories Ltd announced the expansion of its commercial operations in Europe with the introduction of its portfolio of generics in France. It is intended to be used for the prevention of surgical site infections, following non-emergency, elective colorectal surgery. Under the terms of the agreement, Encore will be responsible for the commercialization of DFD-06 in the United States. This entire portfolio has been transferred to the Company, along with related sales and marketing teams, the manufacturing plant located in Baddi, Himachal Pradesh, and employees. Based on the forensic investigation, no evidence was found of any data breaches leading to personally identifiable information. As of March 31, 2022, there were 90 generic filings awaiting approval with the US Food and Drug Administration (USFDA), comprising 87 ANDAs and 3 NDAs. Dr. Reddy's (WUXI) Pharmaceutical Co. Limited in China ceased to be a step-down subsidiary of the Company with effect from December 13, 2021, consequent to its liquidation.